अApnaFunda
Menu

GLAND PHARMA LIMITED (GLAND)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.78 / 100
Profitability 69Growth 66Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.65 / 100
Price 92Earnings 78FII/DII 24

Passes these screensHigh MomentumNear 52-week high

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹3,302.4 latest close · +34.1% over the last 90 sessions

₹2,500₹3,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹2,500₹3,000Jul 3Sep 4Nov 9

₹3,302.4 month-end · +87.7% over 12 months

₹2,000₹2,500₹3,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹2,000₹2,500₹3,000Nov '25May '26Nov '26

₹3,302.4 month-end · +86.1% over 3 years

₹2,000₹3,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹2,000₹3,000Nov '23May '25Nov '26

₹3,302.4 month-end · +56.3% since Nov '20

₹1,000₹2,000₹3,000₹4,000Nov '20Jan '22Apr '23Jun '24Sep '25Nov '26 ₹1,000₹2,000₹3,000₹4,000Nov '20Nov '23Nov '26

52-week range ₹1573.60 to ₹3374.00 · 1-year volatility 34.0%

Was the rally earned?

+88%share price, 1 yearEarnings and multiple

Both mattered.

  • Per-share earnings added 53 points and the multiple added 35 points (P/E 37.6x to 48.2x).
  • The share count barely moved.
Net profit growth: +53 pts. Points of the price return explained by net profit growing (or shrinking).+53 ptsNet profit growthP/E change: +35 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+35 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +88%+88%Share priceNet profit growth: +53 pts. Points of the price return explained by net profit growing (or shrinking).+53ProfitP/E change: +35 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+35P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +88%+88%Share price
Net profit growth+53 ptsNet profit rose about 47%, which lifts the price.
P/E change+35 ptsThe P/E rose from 37.6x to 48.2x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+86%share price, 3 yearsEarnings and multiple

Both mattered.

  • Per-share earnings added 51 points and the multiple added 35 points (P/E 37.4x to 48.2x).
  • The share count barely moved.
Net profit growth: +51 pts. Points of the price return explained by net profit growing (or shrinking).+51 ptsNet profit growthP/E change: +35 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+35 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +86%+86%Share priceNet profit growth: +51 pts. Points of the price return explained by net profit growing (or shrinking).+51ProfitP/E change: +35 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+35P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +86%+86%Share price
Net profit growth+51 ptsNet profit rose about 45%, which lifts the price.
P/E change+35 ptsThe P/E rose from 37.4x to 48.2x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
-8%share price, 5 yearsLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 11 points, but investors now pay less per rupee of profit (P/E 58.8x to 48.2x), which took 19 points back.
  • The share count barely moved.
Net profit growth: +12 pts. Points of the price return explained by net profit growing (or shrinking).+12 ptsNet profit growthP/E change: −19 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−19 ptsP/E changeShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1 ptsShare count changeShare price: −8%−8%Share priceNet profit growth: +12 pts. Points of the price return explained by net profit growing (or shrinking).+12ProfitP/E change: −19 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−19P/EShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1SharesShare price: −8%−8%Share price
Net profit growth+12 ptsNet profit rose about 13%, which lifts the price.
P/E change-19 ptsThe P/E fell from 58.8x to 48.2x, which lowers the price.
Share count change-1 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-79.3%not yet recovered
1-year volatility34.0%annualised
Beta vs sector index0.793-year daily, correlation 0.37
Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−25%−50%−75%20222023202420252026−78.6% 0%−25%−50%−75%20232025−78.6%
Largest drawdowns

-79.3% (2021-08 peak to 2023-05 low, not yet recovered)

-15.8% (2021-01 peak to 2021-02 low, recovered 2021-03)

Most recent volume spikes

2026-11-09: 6.8x the 50-day median, price +5.4% that day

2026-09-04: 6.1x the 50-day median, price +0.8% that day

2026-08-11: 17x the 50-day median, price +9.6% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

48.2xP/E todayWithin its usual range
Against its own history79th percentile
CheapestMedian 39.6xDearest

Usual range 24.1x to 56.2x since 2020-11.

Against Health Technology48.2x vs 37.0x
This company
48.2x
Sector median
37.0x

30% above the Health Technology median.

12.5x29.9x47.2x64.5xNov '20Feb '22May '23Aug '24Nov '25Nov '2612.5x29.9x47.2x64.5xNov '20Nov '22Nov '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE54th▲ 15 pts vs a year ago
  • Op. margin83rd▲ 11 pts vs a year ago
  • Revenue growth66th▲ 47 pts vs a year ago
  • EPS growth77th▲ 28 pts vs a year ago
  • Debt/equity ↓83rd▲ 5 pts vs a year ago
  • Cash cycle ↓24th▲ 7 pts vs a year ago
  • P/E ↓34th▼ 9 pts vs a year ago
  • 12M momentum89th▲ 20 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~27%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 60.6x, a holder earning 12%/yr needs earnings to grow about 27.2%/yr for 10 years, then trade at 15x.

Delivered−4.3%/yrEPS, last 7 fiscal years · 3-yr avg to 3-yr avg
Gap+31.6 ptsimplied minus delivered
Rank46thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-9%10%30% Nov 2020Nov 2026 -9%10%30% Nov 2020Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x28.7%29.9%31.0%
15x26.1%27.2%28.4%
20x22.8%23.9%25.0%

Drag a slider to test other assumptions

Implied: 27.2%/yr

Looking back

  • Jan 2021Price implied 24%/yr; EPS has since grown 5%/yr (6.0 yrs)
  • Jan 2022Price implied 28%/yr; EPS has since grown 1%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹3302.40
P/E
48.2x
ROCE
15.0%
Market Cap
₹54492 cr
Revenue (TTM)
₹6725 cr
P/S
8.1x
P/B
5.3x
ROE
10.9%
Operating Margin
27.0%
Debt / Equity
0.0x
Promoter Holding
51.8%
12M Momentum
87.7%

52-week range

₹1573.60₹3374.00
96% of the way from its 52-week low to its high

Price risk

1Y volatility
34.0%
Beta vs sector
1-year daily
1.06

Balance sheet & cash

Interest cover
operating profit ÷ interest
62.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.18x
Share count, 1Y
unchanged

Are profits backed by cash?

6 of 7checks within range1 near a threshold
Other income reliance19%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 18.6%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate33%Within range

Median quarterly effective tax rate over about 2.5 years: 33.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.18xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.18x (cash from operations ₹2,943 cr, net profit ₹2,498 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+8 daysWithin range

Debtor days are above the median of the previous three fiscal years by 8 days (107 vs 99). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress8% of fixed assetsWithin range

Capital work-in-progress is 8% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+7 days / 2 yrsWithin range

Days payable changed by +7 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 8.0 pts; promoters trimmed 6.1 pts; FIIs added 3.8 pts.
  • The number of shareholders fell from 1.6 lakh to 1.1 lakh (-33%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters57.9%51.8%-6.1 pts
FIIs4.9%8.7%+3.8 pts
DIIs22.4%30.4%+8.0 pts
Public and others14.8%9.1%-5.7 pts

Number of shareholders

1.1 lakhshareholders-33% since Sep '23
92k1.1L1.4L1.6L Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 1.6 lakh
Dec '23: 1.4 lakh
Mar '24: 1.2 lakh
Jun '24: 1.2 lakh
Sep '24: 1.2 lakh
Dec '24: 1.2 lakh
Mar '25: 1.1 lakh
Jun '25: 1.1 lakh
Sep '25: 97,151
Dec '25: 94,578
Mar '26: 91,500
Jun '26: 1.1 lakh
 92k1.1L1.4L1.6L Sep '23Sep '24Sep '25Jun '26
Sep '23: 1.6 lakh
Dec '23: 1.4 lakh
Mar '24: 1.2 lakh
Jun '24: 1.2 lakh
Sep '24: 1.2 lakh
Dec '24: 1.2 lakh
Mar '25: 1.1 lakh
Jun '25: 1.1 lakh
Sep '25: 97,151
Dec '25: 94,578
Mar '26: 91,500
Jun '26: 1.1 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−3.9%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like GLAND PHARMA LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −22% to +15% vs the market, against +1% for all non-financial companies in the same months.
  • The gap against the base rate (−5.1%, 80% range −14.3% to +0.9%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−60%−40%−20%0%+20%+40%+60%
COHANCE · Feb 2025: −78.4% vs market
NATCOPHARM · Sep 2020: −42.6% vs market
BSOFT · Jan 2024: −41.7% vs market
INTELLECT · Feb 2024: −37.3% vs market
ALKEM · Apr 2020: −33.5% vs market
DRREDDY · Jul 2020: −33.5% vs market
POLYMED · Oct 2024: −32.2% vs market
ESCORTS · Sep 2020: −31.4% vs market
AFFLE · Jun 2025: −29.1% vs market
RALLIS · Jun 2020: −27.0% vs market
SUMICHEM · Jul 2025: −25.3% vs market
EMAMILTD · Jan 2021: −24.2% vs market
FDC · Apr 2020: −22.2% vs market
CERA · Feb 2023: −22.1% vs market
EICHERMOT · Oct 2022: −22.0% vs market
JLHL · Jan 2025: −21.8% vs market
FINCABLES · Apr 2023: −20.4% vs market
CIPLA · Jul 2020: −18.5% vs market
KANSAINER · Mar 2020: −13.7% vs market
CARERATING · May 2025: −11.9% vs market
AIAENG · Mar 2023: −9.2% vs market
PGHL · Apr 2020: −7.5% vs market
NAVINFLUOR · Oct 2020: −6.7% vs market
DHANUKA · May 2020: −6.5% vs market
CARBORUNIV · Aug 2021: −5.1% vs market
RADICO · Mar 2023: −2.7% vs market
IPCALAB · Feb 2020: −0.2% vs market
DIVISLAB · Apr 2025: +0.1% vs market
BOSCHLTD · Mar 2023: +4.3% vs market
PIIND · Feb 2020: +4.4% vs market
ATUL · Apr 2020: +4.4% vs market
NEWGEN · Apr 2024: +4.5% vs market
FORTIS · Jul 2025: +4.6% vs market
TRITURBINE · Feb 2023: +5.0% vs market
KENNAMET · Jul 2022: +6.4% vs market
VOLTAS · Feb 2020: +10.2% vs market
INGERRAND · Sep 2022: +14.2% vs market
SIEMENS · Apr 2023: +14.6% vs market
BALKRISIND · Jul 2020: +14.6% vs market
RATNAMANI · Jan 2023: +15.8% vs market
LINDEINDIA · Jul 2022: +19.5% vs market
POLYCAB · Apr 2023: +19.6% vs market
KSB · Mar 2023: +23.9% vs market
GRINDWELL · Oct 2021: +25.1% vs market
SUPREMEIND · Jun 2023: +27.1% vs market
JBCHEPHARM · Mar 2020: +37.4% vs market
YATHARTH · Sep 2025: +38.5% vs market
CUMMINSIND · May 2023: +40.5% vs market
THYROCARE · May 2025: +41.6% vs market
PERSISTENT · Sep 2020: +69.3% vs market
Similar setups −3.9%All companies +1.2%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−3.9%
All companies' median
+1.2%
Beat the market
46% vs 51%

50 past situations · 50 companies · 31 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
AIAENG
Producer Manufacturing		 Mar 2023 44x17% +79%0% −9%
JBCHEPHARM
Health Technology		 Mar 2020 21x18% +42%−13% +37%
AFFLE
Technology Services		 Jun 2025 73x17% +49%0% −29%
PERSISTENT
Technology Services		 Sep 2020 30x18% +135%0% +69%
IPCALAB
Health Technology		 Feb 2020 39x16% +68%−7% 0%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CARBORUNIV
Process Industries		 Aug 2021 55x19% +208%0% −5%
CUMMINSIND
Producer Manufacturing		 May 2023 52x21% +72%0% +41%
FDC
Health Technology		 Apr 2020 25x17% +42%−6% −22%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, P/S and debt/equity. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to GLAND PHARMA LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

AFFLE 3IAFFLE
Technology Services
76%similar
P/Erevenue growth
SONA BLW PRECISION FORGINGSSONACOMS
Producer Manufacturing
72%similar
revenue growthmarket cap
ITC HOTELSITCHOTELS
Consumer Services
67%similar
market capoperating margin
VARUN BEVERAGESVBL
Consumer Non-Durables
66%similar
operating marginrevenue growth
TIMKEN INDIATIMKEN
Producer Manufacturing
65%similar
promoter holdingP/E
IPCA LABORATORIESIPCALAB
Health Technology
67%similar
market capoperating margin
DIVIS LABORATORIESDIVISLAB
Health Technology
62%similar
promoter holdingEPS growth
SUN PHARMACEUTICAL INDUSTRIESSUNPHARMA
Health Technology
61%similar
EPS growthoperating margin

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since May '23

  1. NovPriceVolume reached 6.8x its 50-day median on 2026-11-09; price +5.4% that day.
  2. AugPriceVolume reached 17.0x its 50-day median on 2026-08-11; price +9.6% that day.
  3. JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
  4. MayPriceVolume reached 76.2x its 50-day median on 2026-05-18; price +15.4% that day.
  5. MarResultsRevenue (TTM) reached a new high of ₹6,113 cr.
  6. MarPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
  7. JanPriceVolume reached 37.9x its 50-day median on 2026-01-29; price +6.5% that day.
  8. DecPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
Show 22 earlier events
  1. NovPriceVolume reached 11.7x its 50-day median on 2025-11-19; price -1.1% that day.
  2. SepResultsYear-on-year EPS growth turned positive.
  3. SepPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
  4. JulPriceVolume reached 10.6x its 50-day median on 2025-07-16; price +4.0% that day.
  5. JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  6. AprPriceVolume reached 17.9x its 50-day median on 2025-04-03; price +1.6% that day.
  7. MarPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
  8. MarPriceVolume reached 27.4x its 50-day median on 2025-03-21; price -0.4% that day.
  9. NovPriceVolume reached 32.8x its 50-day median on 2024-11-05; price +13.8% that day.
  10. SepPromoterPromoter holding fell 6.0 pts to 51.8%.
  11. SepInstitutionsFII + DII holding rose 11.5 pts over 2 quarters to 39.7%.
  12. SepPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
  13. JulPriceVolume reached 9.2x its 50-day median on 2024-07-09; price +7.8% that day.
  14. JunResultsRevenue (TTM) reached a new high of ₹5,664 cr.
  15. JunDividendStarted paying a dividend (payout 43% of profit).
  16. AprPriceVolume reached 84.4x its 50-day median on 2024-04-09; price -3.2% that day.
  17. FebPriceVolume reached 5.5x its 50-day median on 2024-02-15; price -2.7% that day.
  18. NovPriceVolume reached 9.8x its 50-day median on 2023-11-22; price +4.0% that day.
  19. AugPriceVolume reached 21.5x its 50-day median on 2023-08-09; price +3.8% that day.
  20. JunResultsYear-on-year EPS growth turned negative.
  21. JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  22. MayPriceFell 79% from the Aug 2021 peak to the May 2023 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history73 months · 2020-11 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1148.2x₹6725 cr10.9%15.0%0.0x
2026-1045.2x₹6725 cr10.9%15.0%0.0x
2026-0942.3x₹6725 cr10.9%15.0%0.0x
2026-0846.3x₹6431 cr9.9%15.0%0.0x
2026-0740.1x₹6431 cr9.9%15.0%0.0x
2026-0640.0x₹6431 cr9.9%15.0%0.0x
2026-0543.8x₹6113 cr9.3%12.0%0.0x
2026-0434.0x₹6113 cr9.3%12.0%0.0x
2026-0333.0x₹6113 cr9.3%12.0%0.0x
2026-0238.0x₹5802 cr8.6%12.0%0.0x
2026-0138.5x₹5802 cr8.6%12.0%0.0x
2025-1235.9x₹5802 cr8.6%12.0%0.0x
2025-1137.6x₹5721 cr8.4%12.0%0.0x
2025-1041.3x₹5721 cr8.4%12.0%0.0x
2025-0942.6x₹5721 cr8.4%12.0%0.0x
2025-0844.1x₹5617 cr7.7%12.0%0.0x
2025-0748.7x₹5617 cr7.7%12.0%0.0x
2025-0643.2x₹5617 cr7.7%12.0%0.0x
2025-0537.2x₹5729 cr8.1%14.0%0.0x
2025-0432.7x₹5729 cr8.1%14.0%0.0x
2025-0337.2x₹5729 cr8.1%14.0%0.0x
2025-0237.0x₹5890 cr7.9%14.0%0.0x
2025-0136.3x₹5890 cr7.9%14.0%0.0x
2024-1242.4x₹5890 cr7.9%14.0%0.0x
2024-1139.6x₹5857 cr8.3%14.0%0.0x
2024-1037.7x₹5857 cr8.3%14.0%0.0x
2024-0941.0x₹5857 cr8.3%14.0%0.0x
2024-0839.2x₹5664 cr8.9%14.0%0.0x
2024-0745.7x₹5664 cr8.9%14.0%0.0x
2024-0638.9x₹5664 cr8.9%14.0%0.0x
2024-0538.8x₹3625 cr9.8%15.0%0.0x
2024-0436.1x₹3625 cr9.8%15.0%0.0x
2024-0338.9x₹3625 cr9.8%15.0%0.0x
2024-0237.2x₹3625 cr9.8%15.0%0.0x
2024-0141.3x₹3625 cr9.8%15.0%0.0x
2023-1240.6x₹3625 cr9.8%15.0%0.0x
2023-1137.4x₹3625 cr9.8%15.0%0.0x
2023-1032.6x₹3625 cr9.8%15.0%0.0x
2023-0935.3x₹3625 cr9.8%15.0%0.0x
2023-0836.7x₹3625 cr9.8%15.0%0.0x
2023-0727.6x₹3625 cr9.8%15.0%0.0x
2023-0622.4x₹3625 cr9.8%15.0%0.0x
2023-0512.5x₹4401 cr16.9%25.0%0.0x
2023-0418.4x₹4401 cr16.9%25.0%0.0x
2023-0317.2x₹4401 cr16.9%25.0%0.0x
2023-0217.9x₹4401 cr16.9%25.0%0.0x
2023-0117.6x₹4401 cr16.9%25.0%0.0x
2022-1221.4x₹4401 cr16.9%25.0%0.0x
2022-1124.1x₹4401 cr16.9%25.0%0.0x
2022-1024.2x₹4401 cr16.9%25.0%0.0x
2022-0928.4x₹4401 cr16.9%25.0%0.0x
2022-0832.1x₹4401 cr16.9%25.0%0.0x
2022-0730.7x₹4401 cr16.9%25.0%0.0x
2022-0636.6x₹4401 cr16.9%25.0%0.0x
2022-0546.9x₹3463 cr16.9%28.0%0.0x
2022-0452.5x₹3463 cr16.9%28.0%0.0x
2022-0353.7x₹3463 cr16.9%28.0%0.0x
2022-0253.5x₹3463 cr16.9%28.0%0.0x
2022-0156.3x₹3463 cr16.9%28.0%0.0x
2021-1263.4x₹3463 cr16.9%28.0%0.0x
2021-1158.8x₹3463 cr16.9%28.0%0.0x
2021-1060.7x₹3463 cr16.9%28.0%0.0x
2021-0961.0x₹3463 cr16.9%28.0%0.0x
2021-0863.9x₹3463 cr16.9%28.0%0.0x
2021-0764.5x₹3463 cr16.9%28.0%0.0x
2021-0656.2x₹3463 cr16.9%28.0%0.0x
2021-0563.2x₹2633 cr21.2%—0.0x
2021-0455.8x₹2633 cr21.2%—0.0x
2021-0349.7x₹2633 cr21.2%—0.0x
2021-0248.1x₹2633 cr21.2%—0.0x
2021-0142.4x₹2633 cr21.2%—0.0x
2020-1246.9x₹2633 cr21.2%—0.0x
2020-1142.4x₹2633 cr21.2%—0.0x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback